Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology ... licensing deal with AbbVie for an AAV8 gene therapy candidate RGX-314 for ...

RGX-202 also continues to demonstrate the highest reported vector genome copies (4.9-55.4 ... of microdystrophin throughout skeletal and heart muscle using the NAV ® AAV8 vector and a ...

Subfamily subdivisions highlight diverse members, such as the Dependoparvovirus (AAV1-AAV9), organized by genome size (kb), represented by ... Additionally, another study indicates that AAV8 achieves ...

Running a genome-wide CRISPR screen, with single-cell RNA-sequencing ... The candidate is a systemically administered investigational AAV8 gene therapy that drives liver-specific expression of FGF21 ...

Get Instant Summarized Text (Gist) Whole-genome duplication (WGD) has been identified as a key mechanism in long-term adaptation and evolution. In a study using "snowflake" yeast, WGD was found to ...

THE SOCIAL GENOME: The New Science of Nature and Nurture, by Dalton Conley THE DECLINE AND FALL OF THE HUMAN EMPIRE: Why Our Species Is on the Edge of Extinction, by Henry Gee In 2012, NPR ...

ROCKVILLE, Md., March 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY ...

RGX-202 also continues to demonstrate the highest reported vector genome copies (4.9-55.4) measured by qPCR across approved or investigational gene therapies.

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...